Joseph P Balthasar
Overview
Explore the profile of Joseph P Balthasar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen T, Bordeau B, Balthasar J
Mol Cancer Ther
. 2023 Jul;
22(11):1332-1342.
PMID: 37493255
Systemic exposure to released cytotoxic payload contributes to the dose-limiting off-target toxicities of anticancer antibody-drug conjugates (ADC). In this work, we present an "inverse targeting" strategy to optimize the therapeutic...
2.
3.
Nguyen T, Bordeau B, Balthasar J
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765668
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of...
4.
Bordeau B, Nguyen T, Polli J, Chen P, Balthasar J
Mol Cancer Ther
. 2023 Feb;
22(4):459-470.
PMID: 36723609
Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody-drug conjugates (ADC). Deconjugated MMAE readily diffuses into untargeted cells, resulting in...
5.
Nguyen T, Bordeau B, Zhang Y, Mattle A, Balthasar J
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613917
Small therapeutic proteins are receiving increased interest as therapeutic drugs; however, their clinical success has been limited due to their rapid elimination. Here, we report a half-life extension strategy via...
6.
Bordeau B, Balthasar J
Cancer Biol Med
. 2022 Aug;
18(3).
PMID: 35979855
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid...
7.
Chen P, Bordeau B, Zhang Y, Balthasar J
Mol Cancer Ther
. 2022 Aug;
21(10):1573-1582.
PMID: 35930739
We have recently shown that coadministration of mAbs with anti-idiotypic distribution enhancers (AIDE) that inhibit mAb binding to tumor antigens enabled increased intratumoral mAb distribution and increased efficacy of an...
8.
Polli J, Balthasar J
Bioconjug Chem
. 2022 Jul;
33(8):1456-1466.
PMID: 35867869
Cell penetrating peptides conjugated to delivery vehicles, such as nanoparticles or antibodies, can enhance the cytosolic delivery of macromolecules. The present study examines the effects of conjugation to cell penetrating...
9.
Polli J, Chen P, Bordeau B, Balthasar J
AAPS J
. 2022 Mar;
24(3):47.
PMID: 35338415
This work describes use of anti-carcinoembryonic antigen antibodies (10H6, T84.66) for targeted delivery of an endosomal escape peptide (H6CM18) and gelonin, a type I ribosome inactivating protein. The viability of...
10.
Bordeau B, Abuqayyas L, Nguyen T, Chen P, Balthasar J
Front Pharmacol
. 2022 Mar;
13:837744.
PMID: 35250584
Our group has developed and experimentally validated a strategy to increase antibody penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior work, we demonstrated that 1HE, an...